Trusted Mesothelioma & Lung Cancer Resource Since 2003

Mesothelioma Chemotherapy

Q: What are the side effects of mesothelioma chemotherapy?

Common side effects of pemetrexed + cisplatin chemotherapy include fatigue, nausea and vomiting, loss of appetite, low blood cell counts (anemia, neutropenia, thrombocytopenia), kidney toxicity (nephrotoxicity from cisplatin), neuropathy (tingling or numbness in hands and feet), mouth sores, and skin rash. Patients take folic acid and vitamin B12 supplements before and during pemetrexed treatment to reduce the severity of side effects. Most side effects are manageable with supportive medications and resolve after treatment ends.

Q: What happens if first-line chemotherapy stops working?

If mesothelioma progresses after first-line pemetrexed + cisplatin chemotherapy, several second-line options are available. These include gemcitabine (alone or with cisplatin), vinorelbine, retreatment with pemetrexed if the disease remained controlled for 6+ months after initial treatment, and immunotherapy with nivolumab + ipilimumab. Clinical trials may also offer access to novel drugs. The choice of second-line therapy depends on the patient's response to first-line treatment, overall health, and available clinical trial options.

Q: Can mesothelioma patients receive both chemotherapy and immunotherapy?

Yes. Combining chemotherapy with immunotherapy is an active area of research for mesothelioma treatment. While the FDA-approved first-line options are either pemetrexed + cisplatin (chemotherapy) or nivolumab + ipilimumab (immunotherapy), clinical trials are studying sequential and combination approaches. Some patients receive chemotherapy first and then switch to immunotherapy, while others may receive both simultaneously in clinical trial settings. Discuss all available options, including clinical trials, with your oncologist.

Chemotherapy is the most widely used systemic treatment for mesothelioma. The standard first-line regimen of pemetrexed (Alimta) combined with cisplatin was FDA-approved in 2004 and remains a cornerstone of mesothelioma treatment. Whether used as a primary treatment, before surgery (neoadjuvant), or after surgery (adjuvant), chemotherapy plays a critical role in controlling disease progression and extending survival.

12.1 Mo. Median Survival (First-Line)

2004 FDA Approval Year

41% Tumor Response Rate

$0 Upfront Legal Cost

Undergoing Treatment? Get a Free Case Review

Find out if you qualify for compensation. Free, confidential review.

BBB A+ Accredited Since 2009

Super Lawyers Multiple Years Selected

National Trial Lawyers Top 100 Trial Lawyers

AV Preeminent Martindale-Hubbell Rated

AAJ Member American Association for Justice

$2B+ Recovered for Clients

Medically reviewed and updated: February 28, 2026 • Sources: NCI, NCCN, NEJM (EMPHACIS Trial)

First-Line Chemotherapy: Pemetrexed + Cisplatin

The standard first-line chemotherapy regimen for malignant mesothelioma is the combination of pemetrexed (Alimta) and cisplatin. This combination was FDA-approved in February 2004 based on the landmark EMPHACIS trial (Evaluation of Mesothelioma in a Phase III Trial of Pemetrexed with Cisplatin), which demonstrated a significant improvement in overall survival compared to cisplatin alone.

The EMPHACIS Trial

The EMPHACIS trial (Vogelzang et al., published in the Journal of Clinical Oncology, 2003) enrolled 456 patients with previously untreated malignant pleural mesothelioma. The key findings were:

Median overall survival — 12.1 months with pemetrexed + cisplatin vs. 9.3 months with cisplatin alone
Tumor response rate — 41.3% with the combination vs. 16.7% with cisplatin alone
Time to progression — 5.7 months vs. 3.9 months
Improved quality of life — patients in the combination group reported significantly better symptom control and functional capacity

How Treatment Is Administered

Route — intravenous (IV) infusion, administered at an outpatient chemotherapy infusion center
Schedule — one cycle every 21 days (3 weeks). Pemetrexed is infused over 10 minutes, followed by cisplatin over 2 hours
Duration — typically 4 to 6 cycles (approximately 3 to 4.5 months of treatment)
Pre-medications — folic acid supplementation (daily) and vitamin B12 injections (every 9 weeks) are required starting 1 to 2 weeks before the first dose and continuing throughout treatment to reduce toxicity
Hydration — aggressive IV hydration before and after cisplatin to protect kidney function

Pemetrexed + Carboplatin Alternative

For patients who cannot tolerate cisplatin — due to kidney impairment, hearing loss, or severe nausea — pemetrexed + carboplatin is an established alternative. Carboplatin has a more favorable toxicity profile with less nephrotoxicity, less severe nausea, and less neurotoxicity than cisplatin. Studies have shown that pemetrexed + carboplatin produces similar overall survival to pemetrexed + cisplatin, making it a reasonable substitution when cisplatin is contraindicated.

Regimen	Median Survival	Response Rate	Key Advantages
Pemetrexed + Cisplatin	12.1 months	41.3%	FDA-approved standard; best-studied regimen
Pemetrexed + Carboplatin	12.7 months	~32%	Better tolerated; less kidney/neuro toxicity
Cisplatin Alone	9.3 months	16.7%	Rarely used as monotherapy today

12.1 Mo. Median Survival (Pem+Cis)

41% Tumor Response Rate

4–6 Treatment Cycles (Typical)

2004 FDA Approval Year

Second-Line & Salvage Chemotherapy Options

When mesothelioma progresses during or after first-line chemotherapy, second-line treatment options are available. The choice of second-line therapy depends on several factors: how long the disease was controlled by first-line treatment (duration of response), the patient's current health status, and the availability of clinical trials.

Second-Line Chemotherapy Agents

Gemcitabine — a nucleoside analog that can be used alone or in combination with cisplatin or carboplatin. Gemcitabine has shown response rates of 10% to 20% in previously treated mesothelioma patients, with disease stabilization in an additional 30% to 40% of patients.
Vinorelbine — a vinca alkaloid that has shown modest activity in second-line mesothelioma treatment. It is well-tolerated and can be administered on a weekly schedule, making it convenient for patients with limited reserves.
Pemetrexed retreatment — if the disease responded to first-line pemetrexed and remained controlled for at least 6 months after completing initial treatment, retreatment with pemetrexed-based chemotherapy can be effective. Response rates for pemetrexed rechallenge range from 19% to 48% in published studies.
Gemcitabine + ramucirumab — the anti-VEGF antibody ramucirumab combined with gemcitabine has shown improved progression-free survival in the Phase II RAMES trial, representing a targeted therapy approach in the second-line setting.

Immunotherapy as Second-Line Treatment

For patients whose disease progresses after first-line chemotherapy, immunotherapy with nivolumab + ipilimumab has become an important second-line option. While this combination is FDA-approved as a first-line treatment, it is also used after chemotherapy failure, particularly for patients with non-epithelioid cell types who historically have the poorest response to chemotherapy. Single-agent pembrolizumab (Keytruda) and nivolumab (Opdivo) have also shown activity in previously treated mesothelioma patients in clinical trials.

Clinical Trials Offer Additional Options

Clinical trials are critical for advancing mesothelioma treatment and may provide access to investigational drugs that are not yet available through standard care. Patients who have progressed on first-line and second-line therapies should ask their oncologist about available clinical trials. Many mesothelioma clinical trials are actively enrolling patients and may be available at cancer centers nationwide. The National Cancer Institute's clinical trials database (clinicaltrials.gov) is a comprehensive resource for finding open trials.

Medically reviewed and updated: February 28, 2026 • Sources: NCI, NCCN, ACS

Neoadjuvant vs. Adjuvant Chemotherapy

When chemotherapy is used in combination with surgery, the timing of chemotherapy relative to the surgical procedure is an important consideration. Chemotherapy can be given before surgery (neoadjuvant), after surgery (adjuvant), or both (perioperative). Each approach has specific advantages depending on the clinical situation.

Neoadjuvant Chemotherapy (Before Surgery)

Purpose — shrink the tumor burden before surgical resection, making surgery easier and potentially more complete
Typical regimen — 2 to 4 cycles of pemetrexed + cisplatin or carboplatin, followed by reassessment imaging before surgery
Advantages — may reduce tumor size to enable more complete resection; allows assessment of tumor sensitivity to chemotherapy (if the tumor responds, it confirms chemotherapy effectiveness); patients are typically in better overall condition to tolerate chemotherapy before surgery than after
Considerations — delays surgery by 2 to 3 months; in rare cases, the tumor may progress during neoadjuvant treatment, potentially making it unresectable

Adjuvant Chemotherapy (After Surgery)

Purpose — destroy microscopic residual cancer cells that remain after surgical resection, reducing the risk of recurrence
Typical regimen — 4 to 6 cycles of pemetrexed + cisplatin or carboplatin, beginning 4 to 8 weeks after surgery once the patient has recovered sufficiently
Advantages — allows surgery to proceed without delay; targets residual disease that is likely present even after macroscopic complete resection
Considerations — post-surgical recovery may limit the patient's ability to tolerate full-dose chemotherapy; some patients are unable to start or complete adjuvant chemotherapy due to surgical complications

Your Oncology Team Will Determine the Best Approach

The decision between neoadjuvant and adjuvant chemotherapy is made by a multidisciplinary team — including thoracic surgeons, medical oncologists, and radiation oncologists — based on the individual patient's disease characteristics, stage, overall health, and treatment goals. Both approaches have demonstrated benefit when combined with surgery as part of a multimodal treatment plan. The most important factor is receiving treatment at a specialized mesothelioma center with experience in these complex treatment decisions.

Side Effects & Management

Like all cancer treatments, chemotherapy for mesothelioma causes side effects. However, the pemetrexed + cisplatin regimen is generally well-tolerated when appropriate supportive medications are used. Understanding potential side effects and how to manage them helps patients maintain their quality of life during treatment.

Common Side Effects

Fatigue — the most commonly reported side effect; typically worsens over the course of treatment. Light exercise, adequate rest, and good nutrition can help manage fatigue.
Nausea and vomiting — cisplatin is one of the most emetogenic (nausea-causing) chemotherapy drugs. Anti-nausea medications (ondansetron, dexamethasone, aprepitant) are given before and after each treatment cycle to control nausea.
Low blood counts — chemotherapy can suppress bone marrow function, leading to anemia (low red blood cells), neutropenia (low white blood cells, increasing infection risk), and thrombocytopenia (low platelets, increasing bleeding risk). Blood counts are monitored before each cycle.
Kidney toxicity (nephrotoxicity) — cisplatin can damage the kidneys. Aggressive IV hydration before and after each cisplatin infusion is essential. Kidney function is monitored with blood tests before each cycle. If kidney damage occurs, carboplatin may be substituted.
Neuropathy — cisplatin can cause peripheral neuropathy, resulting in tingling, numbness, or burning sensations in the hands and feet. This side effect may be partially or fully reversible after treatment ends, but can be permanent in some cases.
Mouth sores (mucositis) — pemetrexed can cause inflammation and sores in the mouth and throat. Good oral hygiene and prescribed mouth rinses can help prevent and manage mucositis.
Skin rash — pemetrexed may cause a skin rash, which is typically mild and manageable with dexamethasone given before and after each treatment cycle.

Essential Supportive Medications

Folic acid (400–1000 mcg daily) — must begin at least 7 days before the first pemetrexed dose and continue throughout treatment and for 21 days after the last dose. Reduces the risk of serious bone marrow suppression and mucositis.
Vitamin B12 (1000 mcg injection every 9 weeks) — first injection given at least 7 days before the first pemetrexed dose. Works with folic acid to reduce pemetrexed toxicity.
Dexamethasone (4 mg twice daily) — taken the day before, the day of, and the day after each pemetrexed infusion to reduce skin rash and other side effects.

Managing Treatment Costs

Chemotherapy for mesothelioma can be expensive, with treatment costs for a full course ranging from $30,000 to over $100,000 depending on the regimen, location, and insurance coverage. If you or a loved one is undergoing treatment for mesothelioma caused by asbestos exposure, you may be eligible for compensation to help cover medical costs, lost income, and other damages. Contact our attorneys at Danziger & De Llano for a free case review.

Medically reviewed and updated: February 28, 2026 • Sources: NCI, NEJM, NCCN

Chemotherapy + Immunotherapy Combinations

The treatment landscape for mesothelioma has evolved significantly with the FDA approval of immunotherapy (nivolumab + ipilimumab) in October 2020. Patients and oncologists now have two first-line options — chemotherapy and immunotherapy — and research is actively exploring how to combine them for even better outcomes.

Current Treatment Paradigm

Chemotherapy first-line — pemetrexed + cisplatin (or carboplatin) remains the standard for patients with epithelioid cell type who are likely to respond well to cytotoxic therapy
Immunotherapy first-line — nivolumab + ipilimumab is particularly effective for non-epithelioid (sarcomatoid and biphasic) cell types, which respond poorly to chemotherapy
Sequential approach — patients who progress on one class of therapy may benefit from switching to the other. For example, a patient whose disease progresses on chemotherapy may respond to immunotherapy, and vice versa

Emerging Combination Approaches

Clinical trials are actively investigating several combination strategies that pair chemotherapy with immunotherapy or other novel agents:

Chemotherapy + anti-PD-1/PD-L1 immunotherapy — several clinical trials are studying the addition of pembrolizumab or nivolumab to standard pemetrexed + cisplatin chemotherapy. Early results have been promising.
Chemotherapy + anti-angiogenic agents — bevacizumab (Avastin) combined with pemetrexed + cisplatin showed improved survival in the MAPS trial (18.8 months vs. 16.1 months), though bevacizumab is not FDA-approved specifically for mesothelioma.
HIPEC — heated intraperitoneal chemotherapy (using cisplatin at 42–43°C) is used in combination with cytoreductive surgery for peritoneal mesothelioma and represents a distinct form of localized chemotherapy delivery.

Discuss All Options with Your Oncologist

The decision between chemotherapy, immunotherapy, or a combination approach should be made by a multidisciplinary team with mesothelioma expertise. Factors including cell type, stage, PD-L1 expression levels, and the patient's overall health all influence which treatment is most appropriate. Patients should also ask about available clinical trials, which may provide access to the most advanced combination regimens.

$30B+ Available in Asbestos Trust Funds

$1M–$1.4M Average Settlement

100% VA Disability Rating for Meso

$0 Upfront Legal Cost

Diagnosed with Mesothelioma? Get a Free Case Review

If you or a loved one is undergoing chemotherapy or other treatment for mesothelioma, you may be entitled to significant compensation from asbestos trust funds, lawsuits, and VA benefits to help cover medical costs and more. Our experienced mesothelioma attorneys have helped thousands of patients and families recover the compensation they deserve.

$2B+ Recovered Our firm has recovered over $2 billion for mesothelioma and asbestos patients and their families.

No Upfront Fees You pay nothing unless we recover compensation for you. Free and confidential consultation.

35+ Years Experience Danziger & De Llano has been representing mesothelioma patients and families for over three decades.

Nationwide Service Licensed to handle mesothelioma cases in all 50 states from our Houston office.

Or call us 24/7: 1-800-400-1805

FAQ answers reviewed by legal team: February 28, 2026

Frequently Asked Questions About Mesothelioma Chemotherapy

What is the standard chemotherapy for mesothelioma?

The standard first-line chemotherapy for mesothelioma is pemetrexed (Alimta) combined with cisplatin. This combination was FDA-approved in 2004 based on the EMPHACIS trial, which showed it improves median survival to 12.1 months compared to 9.3 months with cisplatin alone, with a tumor response rate of 41.3%. For patients who cannot tolerate cisplatin, pemetrexed + carboplatin is an effective alternative with fewer side effects. Treatment is typically administered intravenously every 21 days for 4 to 6 cycles.

What are the side effects of mesothelioma chemotherapy?

Common side effects of pemetrexed + cisplatin include fatigue, nausea and vomiting, low blood cell counts (anemia, neutropenia, thrombocytopenia), kidney toxicity from cisplatin, peripheral neuropathy (tingling or numbness in hands and feet), mouth sores, and skin rash. Patients must take folic acid (daily) and vitamin B12 (injections every 9 weeks) before and during pemetrexed treatment to reduce side effect severity. Most side effects are manageable with supportive medications and resolve after treatment ends.

What happens if first-line chemotherapy stops working?

If mesothelioma progresses after first-line chemotherapy, several second-line options are available. These include gemcitabine (alone or with cisplatin), vinorelbine, retreatment with pemetrexed if the disease remained controlled for 6+ months, and immunotherapy with nivolumab + ipilimumab. Clinical trials may also offer access to novel drugs. The choice of second-line therapy depends on the response to first-line treatment, the patient's overall health, and available clinical trial options.

Can mesothelioma patients receive both chemotherapy and immunotherapy?

Yes. While the FDA-approved first-line options are either pemetrexed + cisplatin (chemotherapy) or nivolumab + ipilimumab (immunotherapy), patients can receive them sequentially. Many patients start with one approach and switch to the other if the disease progresses. Clinical trials are also studying simultaneous combination approaches. Discuss all available options, including clinical trials, with your oncologist at a specialized mesothelioma treatment center.

This page was last reviewed and updated on February 28, 2026 by the legal and medical team at Danziger & De Llano, LLP.

Sources & References

Have You or a Loved One Been Diagnosed with Mesothelioma?

Mesothelioma is caused by asbestos exposure, and the companies responsible can be held accountable. Whether you are undergoing chemotherapy, exploring treatment options, or caring for a loved one, you may be entitled to significant compensation. Our attorneys at Danziger & De Llano have spent over 35 years helping mesothelioma patients and families get the justice they deserve.

Call 1-800-400-1805 Request a Free Case Review

Free consultation • No obligation • Available 24/7 • No fees unless we win

BBB A+ Accredited 4.8★ Google Rating $2B+ Recovered 35+ Years Experience